{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Tomas A"],"pubmed_abstract":["<h4>Introduction</h4>Cutaneous melanoma (CM) is an aggressive form of skin cancer, with rising incidence and poor prognosis at advanced stages. While early-stage CM typically carries a favorable prognosis, a small subset of patients relapses and progresses to advanced disease, highlighting the need for a deeper understanding of CM biology. Here, we describe the establishment and characterization of a novel patient-derived primary cell line, MelT79, developed from a metastatic lesion of a patient initially diagnosed with stage IB CM, who unexpectedly progressed to advanced disease.<h4>Methods</h4>MelT79 was characterized by multicolor fluorescence in situ hybridization, high resolution comparative genomic hybridization, and targeted next-generation sequencing. Gene and protein expression we"],"journal":["Frontiers in oncology"],"pagination":["1531013"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12313697"],"repository":["biostudies-literature"],"pubmed_title":["A novel patient-derived cutaneous melanoma cell line reveals key features of metastatic melanoma."],"pmcid":["PMC12313697"],"pubmed_authors":["Pojo M","Pereira PM","Farricha V","Rosa JC","Tomas A","Roque L","Moura C","Gouveia E","Albuquerque C","Francisco I","Silva AL","Carvalho E","Cabral MG","Nunes H","Garrido PM"],"additional_accession":[]},"is_claimable":false,"name":"A novel patient-derived cutaneous melanoma cell line reveals key features of metastatic melanoma.","description":"<h4>Introduction</h4>Cutaneous melanoma (CM) is an aggressive form of skin cancer, with rising incidence and poor prognosis at advanced stages. While early-stage CM typically carries a favorable prognosis, a small subset of patients relapses and progresses to advanced disease, highlighting the need for a deeper understanding of CM biology. Here, we describe the establishment and characterization of a novel patient-derived primary cell line, MelT79, developed from a metastatic lesion of a patient initially diagnosed with stage IB CM, who unexpectedly progressed to advanced disease.<h4>Methods</h4>MelT79 was characterized by multicolor fluorescence in situ hybridization, high resolution comparative genomic hybridization, and targeted next-generation sequencing. Gene and protein expression we","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-04-12T15:24:47.713Z","creation":"2026-04-07T13:17:37.537Z"},"accession":"S-EPMC12313697","cross_references":{"pubmed":["40756116"],"doi":["10.3389/fonc.2025.1531013"]}}